Australia’s Island Pharmaceuticals Ltd. surged as much as 47% after saying its experimental antiviral galidesivir had secured regulatory and ethics approvals for emergency use in patients with the Bundibugyo strain of Ebola in Uganda.
Australia’s Island Pharmaceuticals Ltd. surged as much as 47% after saying its experimental antiviral galidesivir had secured regulatory and ethics approvals for emergency use in patients with the Bundibugyo strain of Ebola in Uganda.
<iframe src="https://statesidedaily.com/embed/cluster/12010306a40ccfa5740495993fe8760ccf4dabfc" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Island Pharma Jumps After Emergency-Use Approval for Ebola Drug"></iframe>
